Drugs in Dev. Dermatology
Preclinical
Canada 
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326
Details : TFC-1326 is Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Product Name : TFC-1326
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326
Details : TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies.
Product Name : TFC-1326
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DispersinB
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Marc Edwards
Deal Size : $1.0 million
Deal Type : Private Placement
Kane Biotech Announces Update on Private Placement
Details : The funding will be used primarily for product development including DispersinB and general working capital. The Company has a portfolio of biotechnologies, intellectual property (81 patents) and products developed by the Company's own biofilm research e...
Product Name : DispersinB
Product Type : Enzyme
Upfront Cash : Undisclosed
June 05, 2022
Lead Product(s) : DispersinB
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Marc Edwards
Deal Size : $1.0 million
Deal Type : Private Placement
Lead Product(s) : DispersinB
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DispersinB® wound gel underwent an extensive pre-clinical testing regimen showing it to be safe, non-toxic and non-irritating, in addition, DispersinB® significantly accelerated healing of both infected and non-infected dermal wound compared to control...
Product Name : DispersinB
Product Type : Enzyme
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : DispersinB
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
